Strikingly, VEGF/VEGFR inhibition elevates CXCL12 and CXCR4 expression in the TME of colorectal cancer (CRC) and glioblastoma (74, 75), thus bypassing VEGF-dependent angiogenesis blockade and contributing to tumor recurrence. Here, CXCL12 is linked to neoplasm.